Northeast Clinical Research Center | Bethlehem, PA

Research site
2014 City Line Road, Suite 103, Bethlehem, Pennsylvania, United States of America
Site insights

Top conditions

Kidney Diseases (21 trials)

Polycystic Kidney Diseases (7 trials)

Autosomal Dominant Polycystic Kidney (7 trials)

Chronic Renal Insufficiency (6 trials)

Diabetic Nephropathies (5 trials)

Top treatments

Bardoxolone Methyl

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


12 of 39
Status: Active
Trial type: Interventional
Funder type: Industry

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients (FACT)

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in pati...

Active, not recruiting
Fibrillary Glomerulonephritis
Drug: Acthar Gel 80 UNT/ML Injectable Solution

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: BION-1301

Primary ObjectivesTo assess the safety and tolerability of RGLS8429To assess the impact of RGLS8429 on ADPKD biomarkersSecondary ObjectivesTo assess...

Polycystic Kidney, Autosomal Dominant
Drug: RGLS8429
Drug: Placebo

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegce...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Drug: Pegcetacoplan

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the t...

Diabetic Kidney Disease
Drug: Placebo
Drug: INV-202

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients wi...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Other: Placebo
Drug: Pegcetacoplan

This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiot...

Active, not recruiting
Focal Segmental Glomerulosclerosis
Drug: Irbesartan
Drug: RE-021 (Sparsentan)

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease.

Active, not recruiting
Kidney Diseases
Diagnostic Test: Renasight

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: Placebo Multiple Doses
Drug: BION-1301 Single Dose

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Chronic Kidney Disease
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial sponsors


Palladio Biosciences (3 trials)

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS) (2 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems